What is Genedrive?
Genedrive plc is a UK-based pharmacogenetic testing company focused on developing and commercializing a cost-effective, rapid, and adaptable point-of-need pharmacogenetic platform. This innovative platform is designed to assist clinicians in making critical decisions regarding medication or dosage, particularly within emergency healthcare environments. The company's key offerings include the Genedrive® MT-RNR1 ID Kit for neonatal intensive care and the Genedrive® CYP2C19 ID Kit for stroke patient care, both of which have received recommendations for adoption by the UK National Health Service (NHS).
How much funding has Genedrive raised?
Genedrive has raised a total of $12.4M across 2 funding rounds:
Other Financing Round
$7.6M
Stock/Share Issuance
$4.8M
Other Financing Round (2024): $7.6M, investors not publicly disclosed
Stock/Share Issuance (2025): $4.8M, investors not publicly disclosed
What's next for Genedrive?
The substantial enterprise-level backing positions Genedrive for accelerated growth and market penetration. This strategic investment is likely to fuel further research and development, enhance manufacturing capabilities, and expand the commercial reach of its diagnostic kits. The company's focus on critical care applications suggests a trajectory aimed at integrating its pharmacogenetic solutions more deeply into routine clinical practice, potentially leading to improved patient outcomes and more personalized medicine approaches.
See full Genedrive company page
